Menarini Industrie Farmaceutiche Riunite: Menarini Group Shares NEXPOVIO® (selinexor) Subgroup Data from BOSTON trial at the European Hematology Association Congress, Highlighting Clinical Potential in Relapsed/Refractory Multiple Myeloma

Data demonstrate a significant 71% reduction in risk of disease progression or death in selinexor + bortezomib + dexamethasone (SVd) arm versus bortezomib + dexamethasone (Vd) arm in PI-naïve

Related Keywords

Germany ,Italy ,Iceland ,Austria ,Norway ,United States ,Spain ,Turkey ,United Kingdom ,Liechtenstein ,Northern Ireland ,Craigavon ,Salamanca ,Castillay Leóp ,Switzerland ,Boston ,Massachusetts ,Zeiten ,Mecklenburg Vorpommern ,America ,Italian ,Elcin Barker Ergun ,Maria Victoria Mateos ,Stefan Klotter ,Menarini Group ,Stemline Therapeutics Inc ,Karyopharm Therapeutics Inc ,European Hematology Association ,European Commission ,World Health Organization ,Linkedin ,University Hospital Salamanca ,Stemline Therapeutics ,Professor Maria Victoria Mateos ,Meeting Presentation ,Lenalidomide Refractory Multiple Myeloma ,Subgroup Data ,Karyopharm Therapeutics ,European Economic Area ,Middle East ,Multiple Myeloma ,Product Characteristics ,European Public Assessment Report ,Therapeutics Inc ,Stabile Ertr ,Chart Profi Stefan Klotter ,Blue Chips ,Menarini ,Ndustrie ,Armaceutiche ,Yiunite ,Group ,Hares ,Expovio ,Selinexor ,Subgroup ,Data ,Rom ,Trial ,European ,Hematology ,Association ,Congress ,Ighlighting ,Linical ,Potential ,Relapsed ,